Fat Loss and Metabolism
All articles
-
SLU-PP-332, known as an exercise mimetic – how does it work?
SLU-PP-332 was added to the Prohibited List by name before anyone had given it to a human being in a clinical trial. PubMed holds a dozen or so papers on it, ClinicalTrials.gov not a single study, and yet from 1 January 2027 it sits beside meldonium and trimetazidine in the class of metabolic modulators.
Marek Wawrzyk -
Orforglipron, the First Non-Peptide GLP-1 Receptor Agonist in a Tablet
Orforglipron does not work in mice or rats. The molecule binds a part of the GLP-1 receptor that differs between rodents and primates, so its preclinical studies needed animals carrying the human receptor.
Marek Wawrzyk -
Cagrilintide — a long-acting amylin analogue: mechanism and scientific evidence
Cagrilintide is a synthetic analogue of amylin, a hormone the pancreas releases together with insulin. Novo Nordisk designed it to act for a week and studies it mainly in combination with semaglutide under the name CagriSema.
Marek Wawrzyk -
Semaglutide: Mechanism, Registration Trial Program and Regulatory Status
Semaglutide has the most extensive evidence base of any compound discussed on this blog.
Marek Wawrzyk -
Fat Burner Ranking 2026
The lists of "fat burning" substances have one common drawback: it is not known how they were ranked.
Marek Wawrzyk -
Tirzepatide vs. Semaglutide – Which Is Better for Weight Loss?
This article compares the pharmacology of two incretin molecules using evidence from registration trials.
Marek Wawrzyk
6 z 11 posts